NEW YORK, May 5, 2017 /PRNewswire/ --
On Thursday, the NASDAQ Composite ended the day at 6,075.34, up 0.05%; theDow Jones Industrial Average edged 0.03% lower, to finish at 20,951.47; and the S&P 500 closed at 2,389.52, slightly gaining 0.06%. Gains were broad based as five out of nine sectors finished the trading session in green. Stock-Callers.com has initiated
On Thursday, shares in Ewing, New Jersey headquartered Antares Pharma Inc. ended the session 1.00% higher at $3.03 with a total volume of 1.83 million shares traded. Antares Pharma's shares have gained 3.77% in the last one month and 37.10% in the previous three months. Furthermore, the stock has rallied 212.37% in the past one year. The stock is trading 10.38% above its 50-day moving average and 51.31% above its 200-day moving average. Moreover, shares of the Company, which focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide, have a Relative Strength Index (RSI) of 58.92.
On April 21st, 2017, research firm Raymond James initiated a 'Strong Buy' rating on the Company's stock. ATRS complete research report is just a click away and free at:
On Thursday, shares in Franklin Lakes, New Jersey headquartered Becton, Dickinson and Co. recorded a trading volume of 1.97 million shares, which was above their three months average volume of 1.18 million shares. The stock ended the day 0.60% higher at $184.86. Shares of the Company, which develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide, are trading at a PE ratio of 30.72. Becton, Dickinson's stock has advanced 0.98% in the last one month and 4.29% in the previous three months. Furthermore, the stock has gained 16.24% in the past one year. The Company's shares are trading above its 50-day and 200-day moving averages by 0.80% and 5.86%, respectively. Furthermore, Becton, Dickinson's shares have an RSI of 53.26. The complimentary report on BDX can be downloaded at:
Plainsboro, New Jersey headquartered Integra LifeSciences Holdings Corp.'s stock finished Thursday's session 0.31% higher at $45.97 with a total volume of 324,143 shares traded. Integra LifeSciences' shares have gained 10.90% and 9.71%, respectively. Furthermore, the stock has surged 30.45% in the past one year. The Company's shares are trading above its 50-day and 200-day moving averages by 7.47% and 9.56%, respectively. Shares of Integra LifeSciences, which develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery, are trading at a PE ratio of 54.47. The stock has an RSI of 70.69.
On May 02nd, 2017, research firm RBC Capital Markets reiterated its 'Sector Perform' rating on the Company's stock with an increase of the target price from $46 a share to $48 a share. Sign up for your complimentary research report on IART at:
Milford, Massachusetts-based Waters Corp.'s stock edged 0.71% higher, to close the day at $173.70. The stock recorded a trading volume of 362,689 shares. Waters' shares have gained 12.19% in the last one month, 19.75% in the previous three months, and 32.87% in the past one year. The Company's shares are trading 9.76% and 15.39% above its 50-day and 200-day moving averages, respectively. Shares of the Company, which operates as an analytical instrument manufacturer in the US and internationally, are trading at a PE ratio of 26.44. Additionally, the stock has an RSI of 78.03. Get free access to your research report on WAT at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Do fad diets really work? Here are some disadvantages and side-effects of going on a fad diet. ...
This is a branch of telemedicine that delivers eye care via a digital medical equipment and ...
Inborn errors of metabolism are genetic disorders that hamper the body''s metabolism resulting in ...View All